Lineage Cell Therapeutics, Inc. (LCTX) News
Filter LCTX News Items
LCTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest LCTX News From Around the Web
Below are the latest news stories about LINEAGE CELL THERAPEUTICS INC that investors may wish to consider to help them evaluate LCTX as an investment opportunity.
3 Penny Stocks to Buy for the Next Bull RunBy corporate protocol and just plain old common sense, when it comes to penny stocks to buy, your first instinct should be this: don’t. |
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call TranscriptLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript November 9, 2023 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.05. Operator: Welcome to the Lineage Cell Therapeutics Third Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call […] |
Q3 2023 Lineage Cell Therapeutics Inc Earnings CallQ3 2023 Lineage Cell Therapeutics Inc Earnings Call |
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateCARLSBAD, Calif., November 09, 2023--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. |
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023CARLSBAD, Calif., November 01, 2023--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 9, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 9, 2023, at 4:30 p.m. Eastern Time/1:30 |
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual MeetingCARLSBAD, Calif., October 24, 2023--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, has been invited to present as part of the "Mapping the Future of Geographic Atrophy" session at Eyecelerator 2023, on Thursday, November 2nd, 2023, at 10am PT. The session will also feature executive presenters from Apellis P |
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging PicksHere are the best longevity stocks to consider. |
Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial CellsCARLSBAD, Calif., October 11, 2023--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,746,324, entitled "Large Scale Production of Retinal Pigment Epithelial Cells". The patent, which has been exclusively licensed to Lineage, has an expected expiration date of July 28, 2036. RG65 |
RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular DegenerationCARLSBAD, Calif., October 05, 2023--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the results of imaging analyses demonstrating rapid improvement in outer retinal structure from patients enrolled in a Phase 1/2a clinical study of RG6501 (OpRegen) (ClinicalTrials.gov Identifier: NCT02286089), which were reviewed by multiple, independent reviewers, were presen |
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023CARLSBAD, Calif., September 19, 2023--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the Cantor Fitzgerald 2023 Global Healthcare Conference, in a fireside chat hosted by Kristen Kluska, Managing Director, Biotechnology Equity Research, Cantor Fitzgerald & Co., on September 27th, 2023 at 9:10 |